ArticleJCO precision oncology2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
Erratum issuedOpen access · hybridAbstract readComment
In one paragraph
Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial.Nature medicine · 2025Trial
- Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation.Current drug targets · 2026Review
- Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Article
- Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Biochemical Society transactions · 2025Review
- Review
- Advances in molecular pathology and therapy of non-small cell lung cancer.Signal transduction and targeted therapy · 2025Review
- Review
- Targeting MET in NSCLC: An Ever-Expanding Territory.JTO clinical and research reports · 2024Review
- Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features.Frontiers in oncology · 2024Article
- [Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.Molecular cancer therapeutics · 2023Review
- Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.Cancer management and research · 2023Review
- Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung Cancer.Clinical lung cancer · 2022Article
- Characterization ofJTO clinical and research reports · 2022Article
- Comprehensive analysis ofTherapeutic advances in medical oncology · 2022Article
- Non-small-cell lung cancer: how to manageDrugs in context · 2022Review
Corrections and comments
- Comment on
- Erratum issuedErratum.2022
Authors and funding
20 authors at 6 institutions in 3 countries.
Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-8554-1185
Lingzhi HongDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6553-3279
Chuck HenselGuardant Health Inc, Redwood City, CA.ORCID 0000-0002-2932-1807
Rongrong ChenGeneplus-Beijing Institute, Beijing, China.
Haley KempDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Niamh ColemanDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5803-9528
Christine A CiunciDivision of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Stephen V LiuDivision of Oncology, Department of Medicine, Lombardi Comprehensive Cancer Center of Georgetown University, Washington, DC.ORCID 0000-0002-4852-3914
Marcelo V NegraoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jennifer YenGuardant Health Inc, Redwood City, CA.ORCID 0000-0002-8580-220X
Xuefeng XiaGeneplus-Beijing Institute, Beijing, China.
Juergen ScheuenpflugMerck KGaA (EMD Serono), Darmstadt, Germany.
Christopher StrohMerck KGaA (EMD Serono), Darmstadt, Germany.
Dilafruz JuraevaMerck KGaA (EMD Serono), Darmstadt, Germany.ORCID 0000-0003-0035-3503
Anne TsaoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-0505-6639
David HongDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8721-1609
Victoria RaymondGuardant Health Inc, Redwood City, CA.ORCID 0000-0001-5223-0981
Paul PaikThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9464-3984
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7872-3477
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USGuardant (United States) · USMerck (Germany) · DEGeorgetown University · USMemorial Sloan Kettering Cancer Center · USUniversity of Pennsylvania · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672
Abstract
MATERIALS AND
methods
resultsOf 40,824 NSCLCs, 692
conclusion
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsExonsGenomicsHumansProto-Oncogene Proteins c-metProto-Oncogene Proteins c-met
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.